Start with the decision, not a fixed menu
The critical question may be: which of six designed VHHs deserves an efficacy experiment; whether a bispecific can be supplied reproducibly; or whether a binding improvement introduced an aggregation liability. These are not identical questions, so identical assay panels are rarely optimal.
Document dose route, expected sample quantity, target biology, concentration needs and time available before selecting the smallest appropriate experimental package. This is an early research screen, not GLP toxicology or formal GMP release testing.
Core measurements—and what they can and cannot tell you
| Attribute | Potential readout | Common interpretive caveat |
|---|---|---|
| Expression & recovery | Soluble expression and purified yield | Strongly depends on construct, system and purification strategy |
| Purity | SDS-PAGE or CE-SDS where appropriate | Denaturing conditions do not replace native aggregation testing |
| Monomer / aggregate | SEC-HPLC / SEC-UPLC | Column interaction and dilution can affect apparent distribution |
| Binding | SPR or BLI kinetic/equilibrium readout | Avidity, mass transport, antigen quality and fitting artifacts matter |
| Conformational stability | nanoDSF / DSF / DSC | A higher Tm alone does not guarantee shelf-life stability |
| Specificity / cell activity | Orthogonal or cell-based assays | Needed for biological relevance, not replaceable by SEC or Tm |
What constitutes an early “red flag”?
- Severely low recoverable yield that makes the intended study impractical.
- High or variable high-molecular-weight species, substantial fragments or inconsistent purity.
- An apparent binding advantage seen only in one assay geometry without supporting controls.
- Poor thermal transition or rapid aggregation under relevant handling stress.
- Unexpected nonspecific interaction or strong dependence on antigen presentation.
A red flag is a reason to investigate or reprioritize, not automatically an absolute fail. No universal Tm, monomer percentage or Kd threshold applies to every antibody format and biological use case.
A useful evidence package combines raw and interpreted data
A well-designed decision dossier should identify sample identifiers, methods, assay conditions, controls, replicate structure, primary plots and quality flags. It should clearly distinguish observed results from model-derived or expert interpretations. Record missing controls and sample limitations as explicitly as favorable results.
Comparability matters: candidates should ideally be tested against comparable antigen lots, study conditions, material quality and assay settings. Otherwise small numerical differences may be misleading.
Small-molecule CMC assumptions do not automatically transfer to antibodies
For antibody discovery, early biophysical risks such as charge heterogeneity, surface hydrophobicity, aggregation and concentration-dependent self-interaction may become relevant. But the extent of assessment should follow the intended molecule and next stage. Expanded formulation, viral safety, PK or immunogenicity programs should be planned when warranted, not implied by an initial screening panel.
Explore our experimental assay options and SPR versus BLI guide. Seq2Study is currently scoping founding research-use pilots, with partner capabilities and prices confirmed project by project.
Scientific context
These external references support the general scientific principles discussed here; they do not validate Seq2Study services or imply a partnership.